NAD+ boosters represent a promising therapeutic approach for neurodegenerative diseases by restoring cellular NAD+ levels, which decline with age and are implicated in neuronal dysfunction.
This page covers NAD+ biology, the rationale for boosting NAD+ in neurodegeneration, preclinical evidence, and clinical development status.
Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme involved in cellular energy metabolism, mitochondrial function, and sirtuin activity. NAD+ levels decline with age in multiple tissues including the brain.
Declining NAD+ impairs mitochondrial function, DNA repair, and cellular stress responses, all of which are relevant to neurodegenerative disease pathogenesis.
Research on NAD+ boosting began with studies on nicotinamide riboside (NR) and other NAD+ precursors showing benefits in animal models of aging and neurodegeneration.
Preclinical studies demonstrate that NAD+ boosters can improve mitochondrial function, enhance neuronal survival, and protect against various neurodegenerative insults. Multiple NAD+ precursors including NR, NMN, and nicotinamide are in clinical trials for age-related conditions and neurodegenerative diseases.
NAD+ (Nicotinamide Adenine Dinucleotide) is an essential coenzyme found in all living cells that plays a critical role in cellular metabolism, energy production, and stress response. NAD+ levels decline with age and in neurodegenerative diseases, making NAD+ boosting therapies a promising therapeutic strategy for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions.
¶ Molecular Structure and Function
NAD+ is an essential coenzyme found in all living cells:
- ** oxidized form (NAD+)**: Functions as an electron acceptor in metabolic reactions
- Reduced form (NADH): Carries electrons to the mitochondria
- NADP+ and NADPH: Related coenzymes for biosynthetic reactions
NAD+ serves as a substrate for several critical enzyme families:
- Sirtuins: NAD+-dependent deacetylases involved in cellular stress response
- PARP enzymes: NAD+-dependent poly(ADP-ribose) polymerases for DNA repair
- CD38/CD157: NAD+-consuming enzymes involved in calcium signaling
NAD+ levels decline dramatically with age:
- Liver: Up to 65% decline
- Skeletal muscle: Up to 80% decline
- Brain: Significant decline in multiple regions
This decline contributes to:
- Mitochondrial dysfunction
- Impaired DNA repair
- Reduced sirtuin activity
- Metabolic disturbances
- Increased neuroinflammation
NMN is a direct precursor in the NAD+ biosynthetic pathway:
- Chemical structure: Nicotinamide + ribose + phosphate
- Conversion: NMN is converted to NAD+ by NMN adenylyl transferase (NMNAT)
- Efficiency: Single-step conversion to NAD+
¶ Sources and Administration
- Endogenous production: From nicotinamide, nicotinamide riboside, and tryptophan
- Dietary sources: Small amounts in vegetables (broccoli, cabbage, avocado)
- Supplementation: Oral, intraperitoneal, and subcutaneous delivery studied
- Rapidly absorbed in the gut
- Transported into cells via specific transporters
- Efficiently converted to NAD+ in multiple tissues including brain
- Dose-dependent NAD+ elevation in blood and tissues
NR is another NAD+ precursor:
- Chemical structure: Nicotinamide + ribose (without phosphate)
- Conversion: NR is phosphorylated to NMN by nicotinamide riboside kinases (NRK)
- Efficiency: Two-step conversion to NAD+
¶ Sources and Administration
- Endogenous production: Minor pathway from nicotinamide
- Dietary sources: Trace amounts in milk and yeast
- Supplementation: Oral delivery most common
- Well-absorbed orally
- Efficiently converts to NAD+ in liver and peripheral tissues
- Crosses the blood-brain barrier
- Generally recognized as safe in human studies
NAD+ boosters enhance mitochondrial health through multiple pathways:
- Sirt1 activation: Increases PGC-1α activity, promoting mitochondrial biogenesis
- Improved electron transport: NAD+ supports Complex I activity
- Reduced oxidative stress: Enhanced antioxidant defenses
- Improved mitophagy: Clearance of damaged mitochondria
NAD+ is essential for DNA repair:
- PARP activation: NAD+ fuels PARP enzymes for single-strand break repair
- SIRT1/SIRT6: Support base excision repair and genome stability
- DNA damage accumulation: Linked to neurodegeneration
NAD+ exerts anti-inflammatory effects:
- SIRT1-mediated deacetylation: Reduces NF-κB inflammatory signaling
- Microglial polarization: Promotes anti-inflammatory phenotype
- Reduced cytokine production: Lower TNF-α, IL-1β, IL-6
NAD+ supports synaptic function:
- SIRT1 activity: Protects against excitotoxicity
- Mitochondrial support: Ensures energy for synaptic transmission
- Axonal protection: Supports neurite outgrowth and maintenance
In AD mouse models, NAD+ boosters have shown:
- Improved cognitive function: Better performance in Morris water maze
- Reduced amyloid pathology: Decreased plaque burden
- Lower tau phosphorylation: Reduced p-tau levels
- Enhanced mitochondrial function: Improved respiration
- Reduced neuroinflammation: Decreased microglial activation
In PD models:
- Protected dopaminergic neurons: Reduced cell death
- Improved motor function: Better performance in behavioral tests
- Enhanced mitochondrial complex I activity: Restored energy metabolism
- Reduced α-synuclein pathology: Decreased aggregation
Benefits observed in:
- Huntington's disease: Improved motor function and survival
- Amyotrophic lateral sclerosis: Delayed disease progression
- Multiple sclerosis: Reduced demyelination
- Stroke: Smaller infarct size and improved recovery
¶ Safety and Tolerability
Human studies have established:
- NMN: Safe at doses up to 500mg daily for extended periods
- NR: Safe at doses up to 1000mg daily
- Minimal side effects: Generally well-tolerated
- No significant adverse events: In published trials
| Compound |
Condition |
Phase |
Primary Outcome |
| NMN |
Alzheimer's disease |
Phase 1 |
Safety, biomarkers |
| NR |
Parkinson's disease |
Phase 2 |
Motor function |
| NR |
MCI |
Phase 1/2 |
Cognitive function |
| NMN |
Age-related cognitive decline |
Phase 1 |
Safety, NAD+ levels |
Clinical trials have measured:
- Blood NAD+ levels: Increased 40-100% with supplementation
- Cognitive scores: Variable effects depending on population
- Metabolic markers: Improved insulin sensitivity in some studies
- Inflammatory markers: Reduced in some trials
| Characteristic |
NMN |
NR |
| Conversion steps |
1 |
2 |
| Oral bioavailability |
High |
Very high |
| Brain penetration |
Demonstrated |
Demonstrated |
| Clinical trial data |
Growing |
Extensive |
| Cost |
Higher |
Lower |
NAD+ boosters may combine with:
- Pterostilbene: Enhanced sirtuin activation
- Resveratrol: Synergistic effects on mitochondria
- PQQ: Additional mitochondrial support
- Exercise: Complementary mechanisms
Potential benefits include:
- Amyloid and tau modulation
- Mitochondrial support for neurons
- Reduced neuroinflammation
- Enhanced DNA repair
Potential benefits include:
- Dopaminergic neuron protection
- Mitochondrial complex I support
- Reduced α-synuclein aggregation
- Motor function improvement
Benefits may include:
- General cognitive enhancement
- Mitochondrial maintenance
- Neuroinflammation reduction
- Synaptic plasticity support
¶ Challenges and Considerations
Questions remain about:
- Dose-response relationships: Not fully established
- Treatment duration: Long-term effects unknown
- Combination therapy: Optimal regimens unclear
- Stage of disease: Effects at different disease stages
Need for:
- NAD+ measurement: Standardized assays
- Target engagement: Biomarkers of biological effect
- Patient selection: Who benefits most
- Treatment response: Predictors of benefit
Current status:
- NMN: Available as supplement; clinical trials ongoing
- NR: Available as supplement; clinical trials ongoing
- Prescription formulations: Not yet approved for neurodegenerative disease
Emerging approaches include:
- NAD+ prodrugs: Enhanced delivery
- Dual-action molecules: Combined mechanisms
- Targeted delivery: Brain-specific formulations
- Gene therapy: Endogenous NAD+ boost
Future trials will explore:
- Multi-target approaches: Combined with other agents
- Personalized medicine: Genotype-guided treatment
- Precision timing: Optimal intervention windows
- Lifestyle integration: With diet and exercise